<DOC>
	<DOCNO>NCT01894516</DOCNO>
	<brief_summary>- 280 patient suffer active rheumatoid arthritis inadequate response methotrexate evaluate improvement disease activity ( efficacy ) take GLPG0634 monotherapy ( 3 different dos - 50mg , 100mg 200mg daily ) match placebo 24 week . - During course study , patient also examine side effect may occur ( safety tolerability ) , amount GLPG0634 present blood ( Pharmacokinetics ) well effect GLPG0634 disease- mechanism action-related parameter blood ( Pharmacodynamics ) determine . Also , effect different dos GLPG0634 administration subject ' disability , fatigue quality life evaluate .</brief_summary>
	<brief_title>Dose-finding Study GLPG0634 Monotherapy Active Rheumatoid Arthritis ( RA ) Patients ( DARWIN2 )</brief_title>
	<detailed_description>- Treatment duration 24 week total . - However , Week 12 , subject placebo subject 50 mg dose achieve 20 % improvement swell joint count ( SJC66 ) tender joint count ( TJC68 ) assign ( automatically via interactive web response system ( IWRS ) ) 100 mg q.d . blind fashion continue treatment Week 24 . - Subjects group maintain randomize treatment Week 24 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>male female subject ≥18 year age day sign informed consent , diagnosis RA since least 6 month meeting 2010 ACR/EULAR criterion RA ACR functional class IIII , ≥6 swell joint ( 66joint count ) ≥8 tender joint ( 68joint count ) Screening Baseline , Screening serum creactive protein ≥ 0.7 x upper limit laboratory normal range ( ULN ) , show inadequate response term either lack efficacy toxicity MTX , agree wash MTX period least 4 week Screening period . current therapy nonbiological disease modify antirheumatic drug ( DMARD ) , exception antimalarial , must stable dose least 12 week prior Screening , current previous RA treatment biologic DMARD , exception biologic DMARDs : administer single clinical study setting , ; 6 month prior Screening ( 12 month rituximab B cell deplete agent ) , ; biologic DMARD effective , discontinue , due lack efficacy , previous treatment time cytotoxic agent , MTX , Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>